Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Mahavir Advanced Remedies Ltd (531689)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531689 NSE: Pharmaceuticals & Drugs | Small Cap | IndoAmerican Advance Share Price
BSE Share Price
Not Listed
Not Listed
Mahavir Advanced Remedies Ltd (531689)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531689 NSE: Pharmaceuticals & Drugs | Small Cap | IndoAmerican Advance Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹171 Cr.
Current Price
₹0
52-Week Low / High
₹151 / 151
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
54.9
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-28.57%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
0.97%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹11.4 Cr.
Face Value
₹10
All Time Low / High
₹7.30 / 374.10
Check Before You Invest
Quality
NAValuation
UndervaluedCheck Valuation charts
Price Trend
Weak
Is Mahavir Advanced Remedies Ltd a good quality company?
Mahavir Advanced Remedies Ltd is a quality company, based on a multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Mahavir Advanced Remedies Ltd performance compare with that of its Peers?
Revenue growth of Mahavir Advanced Remedies Ltd vs industry peers?
Mahavir Advanced Remedies Ltd revenue CAGR is %, compared to the industry median CAGR of 0.00%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Mahavir Advanced Remedies Ltd?
Promoters hold 0.97% of the Mahavir Advanced Remedies Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Mahavir Advanced Remedies Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Mahavir Advanced Remedies Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Mar'12 | Mar'13 | Mar'14 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 0% | 0% | 0% | 0% | 0% | -11.4% | -6.2% | -39.3% | -3.3% | 1.6% | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 0 | 0 | 0 | 0 | 0 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0 |
| Sales YoY Gr. | - | NA | NA | NA | NA | NA | 26.3% | -12.5% | -33.3% | -28.6% | - |
| Adj EPS ⓘ | 0 | 0 | 0 | 0 | 0 | -0.1 | -0.1 | -0.2 | -0.1 | 0.1 | 0.2 |
| YoY Gr. | - | NA | NA | NA | NA | NA | NA | NA | NA | NA | - |
| BVPS (₹) ⓘ | 0 | 0 | 0 | 0 | 0 | 1.5 | 2.4 | 1.5 | 7.6 | 7.7 | 7.9 |
| Adj Net Profit ⓘ | 0 | 0 | 0 | 0 | 0 | -0.1 | -0.1 | -0.1 | -0.2 | 0.1 | 0 |
| Cash Flow from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | -8.2 | 0.5 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | -25.3% | -28.6% | ||||
| Adj EPS ⓘ | NA | NA | NA | NA | ||||
| BVPSⓘ | NA | NA | 48.6% | 1.6% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Mar'12 | Mar'13 | Mar'14 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0 | 0 | 0 | 0 | 0 | -6.7 | -5 | -10.1 | -3.3 | 1.6 | 3 |
| Op. Profit Mgn % ⓘ | 0 | 0 | 0 | 0 | 0 | -9.4 | -3.1 | 9.4 | -118 | -77 | 8.6 |
| Net Profit Mgn % ⓘ | 0 | 0 | 0 | 0 | 0 | -32.8 | -19.6 | -39.2 | -112.1 | 133.9 | 130.6 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 596 | 1,115 | 12,469 | 30,069 | 9,856 |
| Cash Conv. Cycle ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | -386 | 76 | 118 | 189 | 9,848 |
Valuation of IndoAmerican Advance - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Mahavir Advanced Remedies Ltd FAQs
The current trading price of IndoAmerican Advance on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of IndoAmerican Advance stood at ₹171.1 Cr
The latest P/E ratio of IndoAmerican Advance as of 31-Dec-1969 is 660.7.
The latest P/B ratio of IndoAmerican Advance as of 31-Dec-1969 is 19.18.
The 52-week high of IndoAmerican Advance is ₹150.7 and the 52-week low is ₹150.7.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of IndoAmerican Advance is ₹0.20 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Mahavir Advanced Remedies Ltd is a below average quality company.
No data found
No data found
About Mahavir Advanced Remedies Ltd
Indo American Advanced Pharmaceuticals was incorporated on April 29, 1992 was set up to make branded and generic formulations under different systems of medicine such as allopathy, ayurveda and siddha. The company was earlier known as Indo American Advance Pharmaceuticals, it got its present name on December 20, 1996.
The company is located in the Nellore District of Andhra Pradesh, the manufacturing facility was established for manufacturing a variety of formulations including tablets, capsules, liquids and ointments in the field of antibiotics, analgesics, anti-pyretic, antibacterial, anti-inflammatory, and other genres. The company has been suspended from the BSE on account of non-compliance with the listing agreement clauses.
The registered office of the company is located at 24, 2nd Floor, Railway Colony, III Street, NMM Road, Chennai-600029, Tamil Nadu.
You have 41 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
